Login to Your Account

Other News To Note

Thursday, January 6, 2011
• Amira Pharmaceuticals Inc., of San Diego, said findings published in the Journal of Pharmacology and Experimental Therapeutics described the biologic effects and characterization of AM095, a lysophosphatidic acid receptor 1 antagonist in in vitro and in vivo models of fibrotic disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription